An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs

Journal of Pharmacological and Toxicological Methods

Volumn 29, Issue 3, 1993, Pages 129-138

  Handley, S L ^a   McBlane, J W ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Animal model; Anxiety; Elevated X maze

Indexed keywords

2 AMINO 5 PHOSPHONOVALERIC ACID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; ANXIOLYTIC AGENT; BENZODIAZEPINE; BUSPIRONE; CAFFEINE; CHLORDIAZEPOXIDE; DIAZEPAM; DIZOCILPINE; FLUMAZENIL; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN AGONIST; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; BEHAVIOR DISORDER; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW;

ANIMAL; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; RATS;

EID: 0027292902     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8719(93)90063-K     Document Type: Article

References (82)

1. Modelling psychophathology in the laboratory: history and rationale
2. Decreased reactivity to anxiolytics caused by early protein malnutrition in rats
3. Early life protein malnutrition changes exploration of the elevated plus-maze and reactivity to anxiolytics
4. Serotonergic mediation of the anxiolytic effect of intracerebrally injected propranolol measured in the elevated plus-maze
5. Microinjection of propranolol into the dorsal periaqueductal gray causes an anxiolytic effect in the elevated plus-maze antagonised by ritanserin
6. Antagonistic effect of caffeine and yohimbine in animal tests of anxiety
7. Anxiolytic effect of 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines
8. The effects of 5-HT1B characterizing agents in the mouse elevated plus-maze
9. Restraint-induced changes in exploratory behaviour appear to be mediated by norepinephrine-stimulated release of CRF
10. Chronic handling modifies the effect of diazepam in the elevated plus-maze
11. Repeated paroxetine administration in the rat produces an anxiolytic profile in the elevated X-maze and a decreased 3H-ketanserin binding
12. The influence of ritanserin, a serotonin receptor antagonist in anxiety disorders: a double blind placebo-controlled study versus lorazepam
13. Spontaneous activity and brain 5-hydroxyindole levels measured in rats tested in two designs of elevated X-maze
14. Effects of HA-966 on conflict, social interaction and plus-maze behaviors
15. Use of the elevated plus maze to assess anxiolytic potential in the rat
16. Drug action on anxiety models with special reference to serotonergic mechanisms
17. Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors
18. Actions and some interactions of 5-HT1A ligands in the elevated X-maze and effects of dorsal raphe lesions
19. 5-HT and mechanisms of defence
20. Effects of 5-HT1A receptor agonists and NMDA antagonists in the social interaction test and the elevated plus maze
21. Resistance of baseline activity in the elevated plus-maze to exogenous influences
22. Serotonin 1A anxiolytics: an overview
23. One trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze
24. The biological basis of anxiety
25. A theory of benzodiazepine dependence that can explain whether flumazenil will enhance or reverse the phenomenon
26. Can social interactions be used to measure anxiety?
27. Animal models of aversion
28. The elevated T-maze, a new experimental model of anxiety and memory: effect of diazepam
29. Benzodiazepines, putative anxiolytics and animal models of anxiety
30. 5-HT receptors and consolidation of stressful memories
31. Serotonin in animal models of anxiety: the importance of stimulus and response
32. 5-HT—the disengaging transmitter?
33. 5-HT drugs in animal models of anxiety
34. Effects of α2-adrenoceptor agonists and antagonists in a maze exploration model of fear-motivated behaviour
35. Multiple serotonin mechanisms in animal models of anxiety the importance of stimulus and response
36. B receptors mediate the regulation of expoloratory behaviour in the rat
37. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models
38. 5-HT and anxiety
39. Comparison of buspirone and diazepam in generalised anxiety disorder
40. Measures of anxiety and stress in the rat following chronic treatment with yohimbine
41. Enhancement of some 5-HT dependent behavioural responses following repeated immobilization in rats
42. Effects of 8-OH-DPAT and buspirone in a passive avoidance test and in the elevated X-maze test in rats
43. Ipsapirone in the treatment of genera lised anxiety disorder
44. Antinoiceceptive effects of elevated plus-maze exposure: influence of opiate receptor mechanisms
45. Anxiolytic effect of paroxetine in the rat social interaction model of anxiety
46. Interactions of three benzodiazepine receptor inverse agonists with ethanol in a plus-maze test of anxiety
47. The use of a plus-maze to measure anxiety in the mouse
48. Ethologically based animal models of anxiety disorders
49. The involvement of serotonin in psychiatric disorders
50. Evaluation of tricyclic antidepressants in the elevated plus-maze in rats: Anxiolytic effect of dothiepin and doxepin
51. The 5-HT1A ligands BP 554 mimics the anxiolytic activity of buspirone, geprione and ipsapirone in the elevated plus-maze in rats
52. On the modulation of the effects of some 5-HT-related agents in anxiety models
53. An Approach to the Assessment of Anxiety Using the Elevated X-Maze
54. Light intensity influences the response to 8-OH-DPAT in the elevated X-maze
55. Animal models of depression: Review of evidence and implications for research
56. The relationship between fear induced by novel stimulation and exploratory behavior
57. The relation between fear and exploratory behavior
58. Effect of floor surface and environmental illumination on exploratory activity in the elevated plus-maze
59. Effects of 5-HT1A receptor ligands on exploratory behaviour in socially isolated rats
60. An evaluation of the elevated plus-maze test using the novel anxiolytic buspirone
61. Buspirone: A worldwide update
62. Review of the side effect profile of buspirone
63. Effects of some 5-hydroxytryptamine and related ligands in anxiety models
64. Clinical pharmacology of anxiolytics and antidepressants: A psychopharmacological perspective
65. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat
66. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
67. Selective agonists and antagonists for 5-hydroxytryptamine receptor subtypes, and interactions with yohimbine and FG 7142 using the elevated plus maze in the rat
68. Increased 5-HT release in the guinea-pig frontal cortex on exposure to the X-maze
69. Avaliaçao quantitative e qualitativa da ansiedade no labirinto em cruz através de um indice de conflito
70. B receptor antagonist
71. Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery's conflict test
72. Serotonin and behaviour with regard to animal models of anxiety, depression and waiting ability
73. Sex-dependent effects of aversive stimulation on holeboard and elevated plus-maze behavior
74. Anxiolytic effects of benzodiazepines and 5-HT1A agonists: Animal models
75. 1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models
76. Anxiolytic-like activity of the selective 5-HT3 receptor antagonist, BRL 46470A, in the rat elevated X-maze
77. Effects of DN-2327, a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze
78. Animal models as simulants of depression
79. Resocialization of isolation-reared rats does not alter their anxiogenic profile on the elevated X-maze model of anxiety